FDA clears IND application for EVOLVE104 for the treatment of solid tumors
“This IND clearance represents a transformational milestone for our company, as it paves the way for our advancement into a clinical-stage developer of next-generation trispecific T cell engagers,” said Stephen Bloch, M.D., chief executive officer of EvolveImmune. “We have long believed that the integrated CD2 costimulation strategy underpinning EVOLVE has differentiated potential to deliver best-in-class T cell engagers that offer meaningful clinical benefits to patients with cancer. We are excited to evaluate this hypothesis in a clinical setting. We expect to initiate our first-in-human clinical trial for EVOLVE104 in the coming months.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the